Compare FRST & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | AGEN |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 335.6M |
| IPO Year | 2006 | 1999 |
| Metric | FRST | AGEN |
|---|---|---|
| Price | $15.48 | $6.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $18.94 | ★ $26.33 |
| AVG Volume (30 Days) | 110.1K | ★ 1.1M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | ★ 477.27 | 100.00 |
| EPS | 0.68 | ★ 0.96 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $22.97 | $9.64 |
| Revenue Next Year | $8.75 | N/A |
| P/E Ratio | $22.71 | ★ $6.96 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $9.68 | $2.71 |
| 52 Week High | $16.88 | $10.19 |
| Indicator | FRST | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 33.94 |
| Support Level | $15.46 | $2.96 |
| Resistance Level | $15.80 | $8.64 |
| Average True Range (ATR) | 0.32 | 0.62 |
| MACD | 0.02 | -0.29 |
| Stochastic Oscillator | 71.84 | 0.60 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.